Silk Road Medical price target raised to $32 from $24 at Argus

Argus analyst David Toung raised the firm’s price target on Silk Road Medical to $32 from $24 and keeps a Buy rating on the shares. The company recently launched the NPS PLUS and the tapered carotid stent, and with several quarters of solid financial results, Silk Road Medical is continuing on its path to operating profitability, the analyst tells investors in a research note.